[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-anal-fissure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-anal-fissure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,79,140,164,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100644102","female-sexual-function-after-surgery-for-benign-perianal-diseases-100644102",false,"NCT07666035","Female Sexual Function After Surgery for Benign Perianal Diseases","Prospective Evaluation of Female Sexual Function Following Surgical Treatment of Benign Perianal Diseases: A Single-Center Observational Cohort Study","PERISEX","Inclusion Criteria:\n\n* Female patients aged 18-70 years\n* Sexually active during the previous 4 weeks\n* Diagnosed with chronic anal fissure, hemorrhoidal disease, or cryptoglandular anal fistula\n* Scheduled for surgical treatment according to routine clinical indications\n* Able to understand and complete study questionnaires\n* Willing to provide written informed consent\n\nExclusion Criteria:\n\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis)\n* Pregnancy\n* Postpartum period within the previous 12 months\n* Pelvic organ prolapse\n* Previous treatment for female sexual dysfunction\n* Current antidepressant medication use\n* Active psychiatric disorder\n* Gynecological malignancy\n* Previous pelvic radiotherapy\n* Inability or unwillingness to complete study questionnaires\n* Refusal to provide informed consent","FEMALE","18 Years","70 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","Benign perianal diseases such as chronic anal fissure, hemorrhoidal disease, and cryptoglandular anal fistula may negatively affect female sexual function through pain, bleeding, discharge, discomfort, and impairment in quality of life. Although improvement in male sexual function after surgery for benign anorectal disorders has been reported, data regarding female sexual function remain limited.\n\nThis prospective observational cohort study aims to evaluate changes in Female Sexual Function Index (FSFI) scores following surgical treatment of benign perianal diseases. Female patients undergoing surgery for chronic anal fissure, hemorrhoidal disease, or cryptoglandular anal fistula will be assessed preoperatively and at postoperative 3 and 6 months using the FSFI, Cleveland Clinic Incontinence Score (CCIS\u002FWexner), and Visual Analog Scale (VAS).\n\nThe primary objective is to determine whether female sexual function improves following surgical treatment. Secondary objectives include evaluating the relationship between symptom improvement, continence status, pain reduction, and changes in female sexual function.",[26,27,28],"Chronic Anal Fissure","Hemorrhoidal Disease","Cryptoglandular Anal Fistula",[28,26,27,30,31,32],"FSFI","Sexual Functions","Perianal Pain","NOT_YET_RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":22},"2026-08",{"date":41,"type":22},"2028-02",{"name":43,"class":44},"Gazi University","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100632966","comparison-of-lateral-internal-sphincterotomy-techniques-for-chronic-anal-fissure-100632966","NCT07520552","Comparison of Lateral Internal Sphincterotomy Techniques for Chronic Anal Fissure","A Prospective Randomized Controlled Trial Comparing Spasm-Controlled, Fissure Apex-Limited, and Dentate Line-Limited Lateral Internal Sphincterotomy Techniques in Chronic Anal Fissure","SPHINX","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of chronic anal fissure (duration ≥8 weeks)\n* Failure to heal after at least 6 weeks of appropriate medical treatment (topical agents, fiber supplementation, sitz baths)\n* Complete preoperative fecal continence (Wexner Incontinence Score = 0)\n* Primary anal fissure (posterior or anterior midline location)\n* Written informed consent\n\nExclusion Criteria:\n\n* Any degree of preoperative fecal incontinence\n* Secondary anal fissure (associated with Crohn's disease, tuberculosis, HIV, syphilis, or other systemic conditions)\n* Previous anal sphincter surgery\n* History of obstetric sphincter injury\n* Active anorectal infection (abscess or fistula)\n* Pregnancy or breastfeeding\n* Uncorrectable coagulopathy or current anticoagulant use\n* Inability to cooperate with study procedures or attend follow-up visits","ALL",{"count":55,"type":22},150,"INTERVENTIONAL",[58],"NA","This prospective randomized controlled trial compares three lateral internal sphincterotomy (LIS) techniques in patients with chronic anal fissure refractory to medical treatment: (1) Spasm-Controlled LIS (serial small sphincterotomies using an anal calibrator until 30 mm anal caliber is achieved, under local anesthesia plus sedation), (2) LIS up to the Fissure Apex (spinal or general anesthesia), and (3) LIS up to the Dentate Line (spinal or general anesthesia). The primary outcomes are fissure healing rate and fecal incontinence incidence at 12 months, assessed using the Wexner Incontinence Score. Secondary outcomes include postoperative pain (VAS), recurrence rate, patient satisfaction, and complications. A total of 150 patients (50 per group) will be enrolled and followed for 12 months.",[26],[62,63,64,65,66,67],"Chronic anal fissure","Lateral internal sphincterotomy","Spasm-controlled sphincterotomy","Fecal incontinence","Dentate line","Fissure apex","RECRUITING","2026-05-12",{"date":71,"type":37},"2026-05-14",{"date":73,"type":37},"2026-05-06",{"date":75,"type":22},"2028-05-06",{"name":77,"class":44},"Çanakkale Onsekiz Mart University",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":56,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100611443","phase-4-outcomes-from-hyperbaric-oxygen-hbo2-treatment-for-emerging-indications-100611443","NCT07240649","Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons",{"count":87,"type":22},100,[89],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,26,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Raynaud Syndrome","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Tinnitus","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Osteonecrosis","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","Cartilage Injury","2026-05-01",{"date":134,"type":37},"2026-05-05",{"date":39,"type":22},{"date":137,"type":22},"2035-12",{"name":139,"class":44},"Jay C. Buckey Jr.",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":56,"phases":150,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":78},"100551129","phase-1-e-cel-uvec-treatment-for-anal-fissures-100551129","NCT06456073","E-CEL UVEC Treatment for Anal Fissures","An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC Cell Therapy for the Treatment of Chronic Anal Fissure","Inclusion Criteria:\n\n1. Adults 18 years and older\n2. Anterior or posterior chronic anal fissure (CAF) - chronicity defined as presence of anal fissure ≥ 6 weeks\n3. Inadequate response to medical treatment of anal fissure (1 month of failed vasodilator treatment plus declined or failed botulinum injection treatment)\n4. Recent history of pain on defecation at a level 4 or higher on the numerical rating scale (NRS)\n5. Vital signs upon screening:\n\n   * Blood pressure: systolic ≥ 90 and \\\u003C 140; and diastolic ≥ 60 and \\\u003C 90.\n   * Breathing: ≥ 12 and ≤ 20 breaths per minute.\n   * Pulse: ≥ 60 and ≤ 100 beats per minute.\n   * Temperature: ≥ 97.8°F and ≤ 99.1°F (36.5°C to 37.3°C)\n   * O2 saturation: \\> 92%\n6. Willing to take adequate contraceptive measures\n7. Willing to sign an informed consent form and follow instructions for the trial including appearing for visits and filling out questionnaires\n\nExclusion Criteria:\n\n1. Lateral anal fissure\n2. Presence of peri-anal or rectovaginal fistula, rectal or anal stenosis, or peri-anal abscess or non-healing peri-anal post-surgical wounds that are not anal fissures (subjects with history of anorectal surgery with healed surgical wound is not excluded)\n3. Active, untreated or medically unresponsive infection of the anal fissure or fistula (e.g., erythema and pus)\n4. Active systemic infection (e.g., bacteremia, sepsis) - stable, controlled and treated HIV+ subjects (e.g., recent plasma HIV RNA \\\u003C200 copies\u002FmL) are not excluded\n5. Presence of inflammatory bowel diseases (e.g., Crohn's, ulcerative colitis)\n6. Taking systemic chemotherapy or local pelvic radiation treatments\n7. Renal impairment defined by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\n8. Hepatic impairment defined by both of the following laboratory ranges:\n\n   (a) total bilirubin ≥ 1.5 x ULN unless benign congenital hyperbilirubinemia; and (b) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2.5 x ULN\n9. Active alcohol or substance use that, in the opinion of the site investigator, will interfere with study follow-up.\n10. Active malignant tumor (tumors must be in remission for ≥ 6 months without maintenance chemotherapy and\u002For radiation)\n11. Ongoing or recent history (within 6 months) of abnormal, severe, progressive, or uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases\n12. Congenital immunodeficiencies\n13. History of major surgery or severe trauma within the previous 3 months\n14. Subjects who are actively being considered as candidates for solid organ transplantation or who may have a high likelihood of needing a solid organ transplant (ex. Progressive heart failure)\n15. Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed during the study (180 days)\n16. Subjects who have known hypersensitivity or documented allergy to DMSO\n17. Subjects who do not wish to or cannot comply with study procedures",true,{"count":149,"type":22},20,[151],"PHASE1","This clinical trial is being conducted by investigators who are colorectal surgeons. Eligible study participants will receive the experimental treatment E-CEL UVEC cells by direct injection into the anal fissure. The study is being conducted to determine if E-CEL UVEC cell injections will be safe and would have any effects on healing of the anal fissure.",[26],[26],"2026-04-02",{"date":157,"type":37},"2026-04-08",{"date":159,"type":37},"2024-09-12",{"date":161,"type":22},"2026-12",{"name":163,"class":44},"Weill Medical College of Cornell University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":19,"enrollmentInfo":170,"targetDuration":4,"studyType":56,"phases":172,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":78},"100613566","combined-method-of-surgical-treatment-of-anal-fissure-100613566","NCT07268261","Combined Method of Surgical Treatment of Anal Fissure","Inclusion Criteria:\n\n* • Patients with chronic anal fissure with spasm of anal sphincter\n\nExclusion Criteria:\n\n* • Inflammatory diseases of the colon\n\n  * Pectenosis\n  * Previous surgical interventions on the anal canal\n  * IV grade internal and external hemorrhoids\n  * Rectal fistula\n  * Severe somatic diseases at the decompensation stage\n  * Pregnancy and lactation\n  * Anal sphincter insufficiency\n  * Chronic paraproctitis\n  * Individual intolerance and hypersensitivity to botulinum toxin\n  * Myasthenia gravis and myasthenic syndromes\n  * History of allergic reaction to anticoagulants.\n  * Blood diseases (thrombocytopenia, splenomegaly, etc.)",{"count":171,"type":22},122,[58],"The purpose of this study is to improve treatment outcomes for patients with chronic anal fissure.",[26],[176,177,178,179,65,180,181],"Fissure in Ano","Anal fissure","botulinum toxin A","Chronic anal pain","Spasm of the internal sphincter","Anal sphincter insufficiency","2025-12-03",{"date":184,"type":37},"2025-12-05",{"date":186,"type":37},"2023-09-01",{"date":188,"type":22},"2026-09-01",{"name":190,"class":191},"State Scientific Centre of Coloproctology, Russian Federation","OTHER_GOV",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100591759","relief-study-resolving-fissures-with-lateral-internal-sphincterotomy-100591759","NCT06984601","RELIEF Study: Resolving Fissures With Lateral Internal Sphincterotomy","RELIEF Study: Resolving Fissures With Lateral Internal Sphincterotomy - Evaluating Function and Quality of Life: A National, Prospective Cohort Study","RELIEF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosed with chronic anal fissure (symptoms lasting more than 6 weeks)\n* Decision for lateral internal sphincterotomy (LIS) made by the treating physician\n* Able to understand and complete study-related questionnaires\n\nExclusion Criteria:\n\n* Presence of other anorectal or rectal diseases (e.g., fistula, abscess, inflammatory bowel disease)\n* History of prior anal surgery or pelvic radiation\n* Inability to comprehend study-related forms or provide informed consent",{"count":201,"type":22},300,"The goal of this observational study is to learn how a common surgery called lateral internal sphincterotomy (LIS) affects people with chronic anal fissures, a painful tear near the anus. The study will look at whether this surgery helps lower problems like pain and incontinence, and how it affects quality of life and mental health.\n\nThe main questions the study aims to answer are:\n\nDoes LIS surgery lower the rate of incontinence one year after surgery? Does it improve quality of life, reduce pain, and increase patient satisfaction?\n\nParticipants will:\n\nHave surgery for chronic anal fissure called LIS. Complete short surveys about pain and mental health at 1 week, 3 months, and 12 months.\n\nAnswer questions about bowel function, incontinence and daily life at 3 and 12 months.\n\nResearchers will follow about 300 adults at hospitals across the Turkey. This study will help improve future treatment decisions and make surgery safer and more effective.",[26],[62,63,65],"2025-05-21",{"date":207,"type":37},"2025-05-22",{"date":209,"type":22},"2025-06-01",{"date":211,"type":22},"2027-05-31",{"name":213,"class":44},"Turkish Society of Colon and Rectal Surgery"]